Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
UCB Biopharma SRL
Joseph F Merola; Robert Landewé; Iain B McInnes; Philip J Mease; Christopher T Ritchlin; Yoshiya Tanaka; Akihiko Asahina; Frank Behrens; Dafna D Gladman; Laure Gossec; Alice B Gottlieb; Diamant Thaçi; Richard B Warren; Barbara Ink; Deepak Assudani; Rajan Bajracharya; Vishvesh Shende; Jason Coarse; Laura C Coates